At present, PD-L1 is one of the biomarkers for non-small-cell lung cancer patients to choose immune checkpoint inhibitor (ICI) therapy, in which the expression of PD-L1 is used as a prognostic indicator for NSCLC patients receiving palivizumab therapy [15], but the expression of PD-L1 and its related influencing factors in the real world is still unclear. This evidence concerns the gene CD274 and non-small cell lung carcinoma.